Preclinical studies, such as C1q-deficient mouse models, reveal impaired placentation and preeclampsia-like features, while models like the BPH mouse demonstrate complement-driven inflammation and fetal loss, mitigated by inhibitors like CR2-Crry. This evidence concerns the gene CR2 and preeclampsia.